Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 7/20 | 0.40 |
| ▸ | MAOA | P21397 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234026 | 0.74 | HRH3 (0.46) | TP53HRH3CREBBPKDM1AMAOB | |
| SCHEMBL17771702 | 0.72 | HRH3 (0.52) | TP53HRH3CREBBPKDM1AMAOB | |
| SCHEMBL11516737 | 0.70 | HRH3 (0.44) | TP53HRH3CREBBPKDM1AMAOB | |
| SCHEMBL17771778 | 0.69 | HRH3 (0.52) | TP53HRH3MAOBMAOAMEN1 | |
| SCHEMBL23774201 | 0.69 | HTR2A (0.54) | HRH3CREBBPKDM1AMAOBMAOA | |
| SCHEMBL29850459 | 0.67 | MAOB (0.50) | HRH3KDM1AMAOBMAOAALOX5 | |
| SCHEMBL29289912 | 0.66 | TOP1 (0.51) | HRH3CREBBPMAOBMAOAMEN1 | |
| SCHEMBL31098495 | 0.66 | TOP1 (0.51) | HRH3CREBBPMAOBMAOAMEN1 | |
| SCHEMBL10817164 | 0.66 | KCNE1 (0.50) | CREBBPMAOBMAOANPC1RAB9A | |
| SCHEMBL8675711 | 0.65 | PPARG (0.50) | MAOBMAOANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| EP-1507763-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097607-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | PPARD, PPARG, PPARA | TP53 4537/4885HRH3 800/4885CREBBP 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.